GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced appetite.

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class ...

Semaglutide (Ozempic) improves blood sugar control and weight loss in people with type 1 diabetes and obesity using insulin pumps, new study shows.

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global healthcare company, ...

Novo Nordisk, a leading global healthcare company, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ...

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor (UPDATED) ...

A late-stage study showed that the drug, called orforglipron, appeared to be about as effective as a weekly Ozempic injection at inducing weight loss and lowering blood sugar.

Semaglutide, a common diabetes and weight loss medication, can have several long-term side effects. Despite this, experts generally consider it safe and effective.

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities ...